NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE262192 Query DataSets for GSE262192
Status Public on Mar 30, 2024
Title PEGboIFN-lambda as a FMD preexposure prophylactic and vaccine adjuvant in cattle—ISG and adaptive immunity gene expression
Organism Bos taurus
Experiment type Expression profiling by RT-PCR
Summary Foot-and-mouth disease (FMD) is a vesicular disease of cloven-hoofed animals with devastating economic implications. The current FMD vaccine, routinely used in enzootic countries, requires at least 7 days to induce protection. However, FMD vaccination is typically not recommended for use in non-enzootic areas, underscoring the need to develop new fast-acting therapies for FMD control during outbreaks. Interferons (IFNs) are among the immune system’s first line of defense against viral infections. Bovine type III IFN delivered by a replication defective adenovirus (Ad) vector has effectively blocked FMD in cattle. However, the limited duration of protection—usually only 1-3 days post-treatment (dpt)—diminishes its utility as a field therapeutic. Here we test whether polyethylene glycosylation (PEGylation) of recombinant bovine IFNλ3 (PEGboIFNλ3) can extend the duration of IFN-induced prevention of FMDV infection in both vaccinated and unvaccinated cattle. We treated groups of heifers with PEGboIFNλ3 alone or in combination with an adenovirus-based FMD O1Manisa vaccine (Adt-O1M) at either 3 or 5 days prior to challenge with homologous wild type FMDV. We found that pre-treatment with PEGboIFNλ3 was highly effective at preventing clinical FMD when administered at either time point, with or without co-administration of Adt-O1M vaccine. PEGboIFNλ3 protein was detectable systemically for >10 days and antiviral activity for 4 days following administration. Furthermore, in combination with Adt-O1M vaccine, we observed a strong induction of FMDV-specific IFNγ+ T cell response, demonstrating its adjuvanticity when co-administered with a vaccine. Our results demonstrate the promise of this modified IFN as a pre-exposure prophylactic therapy for use in emergency outbreak scenarios.
 
Overall design 112 Samples, 3 biological replicates per treatment condition and time point and two technical replicates per sample.
 
Contributor(s) Attreed SE, Silva C, Rodriguez-Calzada M, Mogulothu A, Abbott S, Azzinaro P, Canning P, Skidmore L, Nelson J, Knudsen N, Medina GN, de los Santos T, Díaz-San Segundo F
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Mar 21, 2024
Last update date Mar 30, 2024
Contact name Fayna Diaz San Segundo
E-mail(s) fayna.diazsansegundo@nih.gov
Phone 2409213931
Organization name NIH
Department NIAID-DMID-OBRRTR
Street address 5601 Fisher Ln
City Rockville
State/province MD
ZIP/Postal code 20892
Country USA
 
Platforms (1)
GPL34326 PIADC Mod5 Bovine ISG and Adaptive Immunity Gene RT-qPCR Panels
Samples (112)
GSM8159303 PBMC, PEGboIFNλ3+Ad-O1M(-5dpc) treatment group, timepoint: -5dpc, biological replicate 1, technical replicate 1 and 2
GSM8159304 PBMC, PEGboIFNλ3+Ad-O1M(-5dpc) treatment group, timepoint: -5dpc, biological replicate 2, technical replicate 1 and 2
GSM8159305 PBMC, PEGboIFNλ3+Ad-O1M(-5dpc) treatment group, timepoint: -5dpc, biological replicate 3, technical replicate 1 and 2
Relations
BioProject PRJNA1090536

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE262192_fold-change.txt.gz 7.7 Kb (ftp)(http) TXT
GSE262192_non-normalized.txt.gz 9.6 Kb (ftp)(http) TXT

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap